期刊文献+

左西孟旦对左心功能衰竭患者血浆N-末端脑钠肽前体水平的影响 被引量:3

原文传递
导出
摘要 左西孟旦作为新型正性肌力药一钙增敏剂的一种,由于其具有增加心肌收缩力而不增加心率和心肌耗氧量等优点,被认为很有临床应用前景的新药。
出处 《中国基层医药》 CAS 2012年第10期1545-1546,共2页 Chinese Journal of Primary Medicine and Pharmacy
  • 相关文献

参考文献5

二级参考文献71

  • 1印小荣,段宝祥,何晓虹,张幼祥,李蓬.脑钠素对心功能不全的诊断价值[J].中国现代医药杂志,2005,7(6):8-11. 被引量:5
  • 2Toller WG, Stranz C. Levosimendan, a new inotropic and vasodilator agent. Anesthesiology, 2006, 104: 556-569.
  • 3Haikala H, Nissinen E, Etemadzadeh E, et al. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol, 1995, 25: 794-801.
  • 4Jonsson EN, Antila S, McFadyen L, et al. Population pharmaeokinetics of levosimcndan in patients with congestive heart failure. Br J Clin Pharmacol, 2003, 55: 544-551.
  • 5Antila S, Jarvinen A, Honkanen T, et al. Pharmacokinetic and pharmacodynamic interactions between the novel calcium sensitiser levosi- mendan and warfarin. Eur J Clin Pharmacol, 2000, 56: 705-710.
  • 6Kersten JR, Montgomery MW, Pagel PS, et al. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of KATP channels. Anesth Analg, 2000, 90: 5-11.
  • 7Bowman P, Haikala H, Paul RJ. Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. J Pharmacol Exp Ther, 1999, 288: 316-325.
  • 8Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study) :a randomised double-blind trial. Lancet, 2002, 360: 196-202.
  • 9Moiseyev VS, Poder P, Andrejevs N, ct al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: a randomized, placebocontrolled, double-blind study (RUSSLAN). Eur Heart J, 2002, 23 : 1422-1432.
  • 10Busk M, Maeng M, Kristensen J, et al. Effects of levosimendan on myocardial infarct size and hemodynamics in a closed-chest porcine ischemia-reperfusion model. Cardiovasc Drugs Ther, 2006, 20: 335- 342.

共引文献51

同被引文献31

  • 1慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8234
  • 2Kivikko M, Antila S, Eha J, et al. Pharmacokinetics of levosimen- dan and its metabolites during and after a 24-hour continuous in fusion in patients with severe heart failure. Int J Clin Pharmaeol Ther,2002,40(10) :465-471.
  • 3Gheorghiade M,Teerlink JR, Mebazaa A. Pharmacology of new a- gents for the acute heart failure syndrome. Am J Cardio1,2005,96 (6) :68-73.
  • 4Ng TM. Levosimendan,a new calcium-sensitizing inotrope for heart failure. Pharmacotherapy ,2004,24 ( 10 ) : 1366-1384.
  • 5Mebazaa A, Erhardt L. Levosimendan : a new dual-action drug in the treatment of acute heart failure. Int J Clin Pract, 2003,57 (5) :410-416.
  • 6Cleland JG, Nikitin N, McGowan J. Levosimendan:first in a new class of inodilator for acute and chronic severe heart failure. Ex-pert Rev Cardiovasc Ther,2004,2( 1 ) :9-19.
  • 7Kaheinen P, Pollesello P, Levijoki J. Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart. J Cardiovasc Pharmaco1,2004,43 (4) :555-561.
  • 8Paraskevaidis IA, Parissis LIT, Th Kremastinos D. Anti-inflammato- ry and antiapoptotie effects of levosimendan in decompensated heart failure:a novel mechanism of drug-induced improvement in contractile performance of the failing heart. Curr Med Chem Card- iovase Hematol Agents ,2005,3 ( 3 ) :243-247.
  • 9Michaels AD, McKeown B, Kostal M, et al. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ven- tricular wall stress, and myocardia loxygen uptake. Circulation, 2005,111 (12) : 1504-1509.
  • 10Maytin M, Colucci WS. Cardioprotection:A new paradigm in the management of acute heart failure syndromes. Am J Cardiol, 2005,96 ( Suppl ) : 26 -31.

引证文献3

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部